1999-2000 Department of General and Trauma Surgery, Marien-Hospital Düsseldorf
2001-2010 Department of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen
2001-2004 Residency in Diagnostic and Interventional Radiology
2004 Board Certification in Radiology
2004-2008 Consultant Radiologist
2008-2010 Vice Chairman
since 2010 Chairman of the Department of Diagnostic and Interventional Radiology, University Hospital Düsseldorf
He is the official spokesman on men’s health issues for the BMA, president of the European Mens Health Forum and former president the England & Wales Men’s Health Forum, past vice president of the International Society of Mens Health, past deputy editor of the Mens Health Journal and for six years the medical editor for The Men’s Health Magazine. He has written over 150 books and manuals on health including the NHS Good Health Guide.
Ian was appointed visiting professor of mens health in Europe by Leeds Metropolitan University in 2005 and awarded the Royal Society of Public Health Gold Medal for public health in 2007 followed by appointment to the Academy in 2012. The City of Vienna and the International Society of Mens Health honoured Ian with their award for public health in September 2007. In 2012 the RSPH appointed Ian as Professorial Fellow to the Society. He is now visiting professor to the Universities of Ulster and Leeds along with honorary senior lecturer at Queens University medical school. He currently chairs the European Cancer Organisation (ECCO) patient advisory committee and the European Forum Against Blindness (EFAB). He was appointed vice president of the European Cancer Concord (ECC) in 2015.
Alberto Briganti is Associate Professor of Urology at Vita-Salute University, San Raffaele Hospital, Milan, Italy. He is Chairman of the Prostate Cancer Research Programme and deputy director of the Urological Research Institute at San Raffaele Hospital. Professor Briganti received his medical degree from Vita-Salute University (2002) and a PhD in clinical and experimental biotechnology in Urology from Magna Graecia University, Italy (2016). He completed his residency at San Raffaele Hospital and a fellowship in uro-oncology at the University of Montreal, Canada.
Professor Briganti is a member of scientific committees of several national and international associations, including the European Association of Urology (EAU), the Italian Association of Urology (SIU) and the European Multidisciplinary Meeting on Urological Cancer (EMUC). He is also a fellow of the European Board of Urology and a Faculty member of the European School of Urology (ESU). He is also member of the Guidelines Office Board of the EAU.
Professor Briganti’s main clinical interests include urological oncology, a field in which he has contributed to the development and validation of several prediction models for cancer staging and outcomes that are currently extensively used for patient stratification and treatment. Professor Briganti is Editor in Chief of European Urology Oncology and a member of the editorial boards of several medical journals. He acts as a reviewer for the main urology and oncology journals. Professor Briganti is author and co‑author of more than 600 papers published in peer-reviewed, indexed journals and was the 2016 EAU Crystal Matula Award winner.
Professor Johann de Bono is Regius Professor of Cancer Research and a Professor in Experimental Cancer Medicine at The Institute of Cancer Research and Royal Marsden. He is also the Director of The Drug Development Unit, overseeing the conduct of Phase I trials, with a particular interest in innovative trial designs, circulating biomarkers and prostate cancer. Additionally he leads the Prostate Cancer Targeted Therapy Clinical Trials Team and the Cancer Biomarkers laboratory team.
He has been involved in the development of many novel agents, many of which are now approved drugs, functioning as chief investigator on Phase I trials such as abiraterone, olaparib and afatinib. He has served as chief investigator of multiple drugs that have changed the standard of care for prostate cancer patients including abiraterone, cabazitaxel and enzalutamide and has published more than 300 manuscripts including multiple publications in the New England Journal of Medicine and The Lancet.
Professor of Radiology and Nuclear Medicine at Autonomous University of Barcelona, and Director of the Department of Nuclear Medicine at Hospital Sant Pau in Barcelona, Spain.
Main research and scientific activity in Nuclear Medicine and Molecular Imaging, in particular in the fields of Oncology and Cardiovascular Medicine.
Editor –in-Chief of the European Journal of Nuclear Medicine and Molecular Imaging.
Former President of the European Association of Nuclear Medicine.
Arturo Chiti graduated in Medicine and Surgery at the University of Milan in 1989, and entered the Training Program in Nuclear Medicine, where he got the certification in 1993.
In 1997, he got the European Board of Nuclear Medicine fellowship.
From June 2000, he is Director of Nuclear Medicine Department at the Humanitas Hospital.
On March 2015, he was appointed Full Professor in Diagnostic Imaging and Radiotherapy at the Humanitas University.
He is co-author of several papers and contributed to many abstracts presented at international and national meetings.
He is Editor in Chief of the EJ of Hybrid Imaging and Associate Editor of the EJNMMI.
He is a well-known invited speaker at numerous international congresses and conferences.
Arturo Chiti was the President 2015-16 of the EANM. Is a member of the ECCO Board and of ICRU.
He was awarded the honorary membership of ESTRO; the Tom Miller Memorial Lecture Award from SNMMI and the Hevesy Gyorgy award from the Hungarian Society of NM.
Noel Clarke has been a Consultant Urological Surgeon at the Christie and Salford Royal Hospitals, Manchester, since 1993, and Honorary Professor of Urological Oncology at Manchester University since 2007. He completed his MBBS in London in 1981, his FRCS(Eng) in 1985, his ChM in Manchester 1990 and his urological accreditation and FRCS(Urol) in 1991. Since that time he has specialised in secondary and tertiary referral complex pelvic and retroperitoneal surgery research in to Genito-Urinary malignancy and the delivery of Cancer treatment. He is a nationally and internationally recognised expert in the diagnosis and treatment of cancers of the prostate, bladder, kidney and testis in addition to providing regional and supra-regional surgical provision for complex and rare abdominal tumours such as abdominal / retro-peritoneal sarcoma’s.
Professor Clarke has held the positions of Director of Urology at Salford Royal Hospitals and Director of Surgery at the Christie Hospital, and he coordinated the development of Manchester and Cheshire Urological Cancer Network between 2002 and 2010. He was Chairman of the UK National Cancer Research Institute Prostate Clinical Studies Group between 2003 and 2009, Co-Chairman of the EORTC GU group and was one of 2 Urologists involved in development and publication of the “Improving Outcomes Guidance”, a plan for delivery of Urological Cancer in England from 2002 to 2005. He is currently Director of the Manchester University GU Cancer Research Group, the pan-Manchester biobank and clinical lead for the Manchester / Belfast FASTMAN national centre of Excellence for prostate cancer research and for the National Prostate Cancer Audit in England and Wales. He is a Co-PI of the STAMPEDE and Radicals trials, two of the world’s largest prostate cancer trials and has been involved extensively in national and international cancer trial planning, coordination and data analysis. Professor Clarke’s research interests encompass basic/translational science and Phase I, II, and III trials in urological cancer. He has authored over 220 peer-reviewed papers and 9 book chapters on urology and urological cancer.
Matthias Eiber is board certified radiologist and nuclear medicine physician who was trained at the Institute of Radiology and the Department of Nuclear Medicine at Technical University Munich. After a research fellowship at the Ahmanson Translational Imaging Division in the Department of Molecular and Medical Pharmacology at the University of California Los Angeles (UCLA) he is currently working as attending and assistant professor at the Department of Nuclear Medicine at the Technical University Munich. His main research activity is currently focused on hybrid imaging and prostate cancer theranostics especially the application of prostate specific membrane antigen (PSMA) ligands for imaging, radioguided surgery as well for endoradiotherpy in castration-resistant prostate cancer.
Born in Bologna, Italy, where completed all his studies and graduated at University of Bologna. Started working in conventional nuclear medicine in the ’90, then involved in the project of PET Unit at S.Orsola Policlinic Hospital, participating to site planning then appointed as medical director in 2002. Last year the PET Unit carried out more than 12000 exams, resulting one of the most active in Europe; in particular the PET Center in Bologna is known for the nonFDG scans, in both clinical routine and research area (about 2000 exams last year).
At present he is full time employed in Nuclear Medicine as Professor of Diagnostic Imaging as well as Director of Nuclear Medicine Division and of PET Unit at the S.Orsola Policlinic Hospital. Author of more than 350 full articles published in peer reviewed international journals, several books and chapters; invited lecturer at more than 120 national and international meetings.
Chair of the Oncology Committee of EANM.
K Fizazi, MD, PhD, is a medical oncologist, head of the Department of Cancer Medicine at the Institute Gustave Roussy, and full professor in Oncology at the University of Paris Sud in Villejuif, France.
He has authored numerous abstracts at international congresses and has published over 291 peer-reviewed articles.
Amongst his major achievements, Prof. Fizazi was first to establish the role of early chemotherapy in order to prevent relapse in high-risk localized prostate cancer in the GETUG 12 trial. Prof. Fizazi demonstrated the role of denosumab, for the prevention of complications of bony metastases from prostate cancer. In testicular cancer, Prof. Fizazi could establish in 2014 with the GETUG 13 trial a new standard of care for young patients with poor-prognosis metastatic cancer, thanks to an individualized algorithm of treatment,
Prof Fizazi is involved in many phase I, II, and III clinical trials as a national or global coordinating investigator, including the cabozantinib Comet-1, the abiraterone M1 Latitude, the cabazitaxel-OGX-011 Affinity and the CRPC M0 ODM-201 Aramis large phase III trials in prostate cancer. Prof. Fizazi created in 2013 the Prostate Cancer Consortium in Europe (PEACE). He’s now head of the two first PEACE large European academic phase III trials: PEACE-1 (testing abiraterone and radiotherapy to local primary cancer in de novo metastatic prostate cancer) and PEACE-2 (testing cabazitaxel and pelvic radiotherapy in very high-risk localized prostate cancer).
Prof. Silke Gillessen Sommer, MD, is a senior consultant, specializing in genitourinary tumors, in the Department of Oncology/Hematology at Kantonsspital St. Gallen, St. Gallen, Switzerland, where she also heads the Clinical Trial Unit.
She is a member of several professional societies. From 2007 to 2013, she was president of the SAKK Project Group on Urogenital Tumors.
She is currently the Chair of the EORTC Genito-Urinary Cancers Group.
She served/serves on the ESMO Scientific Subcommittees for GU Oncology 2014/2015/2016.2017 she became chair of Scientific Sub-Committee for Genitourinary tumours (Prostate) for ESMO 2018. From 2016 she is a Member of the ESMO guidelines Committee as deputy for GU malignancies
She is one of the organizers of the St.Gallen Advanced Prostate Cancer Consensus Conference (APCCC) held in 2015 and 2017.
A qualified Nuclear Medicine Technologist, Sam has over a decade of experience in clinical Nuclear Medicine as well as post graduate qualifications in Statistics and an MBA. Sam has worked across the public and private health system in clinical, research and management roles and has spent the last 5 years managing a number of biomedical research projects at the Movember Foundation.
Sam has overarching responsibility for the delivery of the Movember GAP Program, a portfolio of several globally collaborative projects in Prostate and Testicular Cancer Translational Research. One of the early projects in the GAP portfolio is the GAP2 Imaging in Advanced Prostate Cancer project. The GAP2 project was commenced in 2013 and finished in early 2017 and focussed on the development and validation of new-generation tracers to better detect prostate disease as it progresses.
1979-82 Studies in Philosophy and german literature at the university of Heidelberg
1982-88 Studies in medicine at the universities of Marburg, Würzburg and Heidelberg
1988-98 Research physician at the department of Oncological Diagnostics and therapy at the Deutsches Krebsforschungszentrum Heidelberg
since 1998 Professor of Nuclear medicine at the university of Heidelberg, Head of the Dept. of Nuclear Medicine, University of Heidelberg, Head of the Clinical Coop-eration Unit Nuclear Medicine at the Deutsches Krebsforschungszentrum Heidelberg
Editorial board member of Molecular Imaging and Biology, European Journal of Nuclear medicine and Molecular Imaging, Nuklearmedizin, Journal of Nuclear Medicine; Member of SABs Institute for Dutch Cancer Society, DFG, MRC Medical Research Council London UK, Institut national de la sante et de la recherche medicale, Institut national du cancer Paris, Mildred Scheel Foundation, Agence national de la Recherche France
Ken Herrmann is a board certified Nuclear Medicine physician who was trained in the group of Markus Schwaiger at TUM, Germany. He received a MBA degree from University Zürich in 2011. From 2012 to 2016 he served as Vice Chair of Nuclear Medicine at the University of Würzburg. In 2011 Ken Herrmann was added to the faculty of the Ahmanson Translational Imaging Division in the Department of Molecular and Medical Pharmacology at the University of California Los Angeles (UCLA). In 2015 he was tenured at UCLA. Since August 2016 Ken Herrmann is Chair of Nuclear Medicine at Universitätsklinikum Essen, Germany, and serves as Adjunct Professor in the Department of Molecular and Medical Pharmacology at UCLA.
His research focus includes hybrid imaging modalities as well as receptor targeted theranostics with a special focus on prostate cancer. As part of the EANM Oncology Committee he is also involved in the recently published procedure guideline of 68Ga-PSMA PET imaging in prostate cancer.
Rod is a Professorial Fellow of the University of Melbourne and Director of Cancer Imaging at the Peter MacCallum Cancer Centre. Peter Mac installed the first PET/CT outside Europe and North America in 2001 and established the first pre-clinical PET imaging facility in Australia in 2002 enabling a strong focus on translational research. He is actively involved in the therapeutic uses of nuclear medicine, especially for the treatment of neuroendocrine tumours. He holds numerous national and international research grants and is Editor-in-Chief of Cancer Imaging, as well as serving on 6 other editorial boards including Endocrine-Related Cancer. He has over 400 peer-reviewed publications with over 16,000 citations. He received a prestigious National Health and Medical Research Council Program Grant in 2013 and NHMRC Practitioner Fellowship in 2015. He was also induced as a Fellow of the Australian Academy of Health and Medical Science in 2015.
Frederic Lecouvet has been a Full Professor of Radiology at the Radiology Department at Cliniques Universitaires Saint-Luc in Brussels, Belgium, since 2008.
He completed both his medical training (1992) and PhD (1998) at the Université Catholique de Louvain (UCL), Brussels, Belgium.
He is currently associate chair of the Department of Medical imaging, head of the MRI unit, chair of the Imaging Research Pole of the Institut de Recherche Experimentale et Clinique Research at the Cliniques Universitaires Saint-Luc, Brussels, Belgium.
His areas of expertise include imaging of bones, spine, joints, and development of modern imaging techniques to improve the work-up and the assessment of the response to treatment in lesions affecting these organs, particularly bone tumors and metastases.
He authored more than 180 peer reviewed papers, 30 book chapters, 6 books, and gave more than 300 international lectures. He is an elected member of the Royal Academy of Medicine of Belgium.
Rodolfo Montironi, MD and IFCAP, obtained his medical degree at the Medical School of the University of Ancona, Italy in 1976, the board certificate in pathology and laboratory medicine at the University of Parma, Italy, in 1979, and the board certificate in clinical oncology at the University of Ancona in 1982. He is International Fellow of the College of American Pathologists. He is Professor of Pathology at the Medical School of the Polytechnic University of the Marche Region, and, Director of the Uropathology Program, United Hospitals, Ancona, Italy. He is a Past President of the International Society of Urological Pathology. He is the Chairman of the ESUP (EAU Section of Uropathology). He is a member of different international societies of pathology and of urology. Dr Montironi’s work is centered in genitourinary tumor pathology. He is an author or coauthor of more than 700 publications in peer-reviewed international journals.
Joe O’Sullivan is Clinical Director of the Northern Ireland Cancer Centre, Belfast where he works as a Prostate Cancer Oncologist, and Professor of Radiation Oncology at the Centre for Cancer Research and Cell Biology, Queen’s University Belfast.
Joe graduated from University College Dublin medical School in 1993 and trained in Radiation Oncology in St. Luke’s Hospital in Dublin. In 2000 he took up a Clinical research Fellowship at the Royal Marsden London, completing a Doctorate Thesis on the use of high doses of Rhenium-186HEDP with stem cell support in advanced prostate cancer. He was appointed as a senior lecturer and consultant clinical oncologist to Queen’s University Belfast in 2004 and was subsequently appointed as Professor of Radiation Oncology in 2011. He was appointed as Clinical Director of Oncology at The Northern Ireland Cancer Centre, Belfast in 2014.
His research interests include bone-seeking radionuclide therapy in metastatic prostate cancer, translational research in prostate cancer and radiotherapy, and clinical trials in advanced prostate cancer and he has published over 100 research papers. He is one the 4 Directors of the FASTMAN Prostate Cancer Centre of Excellence (Belfast and Manchester) which is 5-year programme of research awarded in 2014 and funded by Movember and PCUK.
Prof. Dr. Ost started his residency in radiation oncology at Ghent University Hospital in 2006. The pioneering position of the Department in the development of novel radiotherapy techniques such as intensity-modulated radiotherapy inspired him to focus his PhD research on the clinical implementation of these techniques in prostate cancer (PCa). He is currently employed at Ghent University Hospital as adjunct chief of clinic and as assistant professor at Ghent University. His research shifted to two main topics: treatment of oligometastatic prostate cancer and the influence of radiotherapy on the immune system.
Professor Wim Oyen was appointed Professor of Nuclear Medicine and Molecular Imaging at The Institute of Cancer Research and Head of the Department of Nuclear Medicine of The Royal Marsden Hospital London, UK in 2015. Before he was Professor of Nuclear Medicine at the Radboud UMC Nijmegen, The Netherlands, serving as Head of the Department of Nuclear Medicine and Director of the Research Institute for Oncology.
His main research interests are molecular imaging in oncology and infectious diseases and radionuclide therapy of cancer. He is the (co-)author of more than 600 articles in international peer-reviewed journals. He is currently actively involved in the European Association of Nuclear Medicine (President-elect, past-Congress Chair), the European Cancer Organisation (Past-Treasurer), the International Cancer Imaging Society (President-elect). He is a member of the Editorial Board of The Journal of Nuclear Medicine and the European Journal of Nuclear Medicine and Molecular Imaging.
Consultant Radiologist Prof. Anwar Padhani MB BS FRCP FRCR is an internationally recognized Oncological MRI radiologist and currently, the clinical lead in MRI at the Paul Strickland Scanner Centre. He is Professor of Cancer Imaging at the Institute of Cancer Research, London. He is specialist in the clinical evaluation of advanced MRI including dynamic MRI, diffusion weighted MRI, MR spectroscopy, whole body MRI and multiparametric MRI of the prostate for primary and metastatic disease. He has a passion for teaching and has published chapters in 31 textbooks, 64 educational and scientific journal reviews in peer reviewed journals, and published over 103 full scientific articles in peer reviewed journals. Prof. Padhani has given over 250 invited lectures at national and international, scientific and educational meetings including several plenary talks. He has to his credit several education related awards including outstanding teacher award from the ISMRM and RSNA.
Jack A Schalken PhD (1959) has an appointment as professor of experimental urology at Radboud University MC, Nijmegen. Dr Schalken was trained as biochemist at the Radboud University Nijmegen, where he also obtained his PhD degree (1987). He did his post doctoral fellowship at Johns Hopkins Hospital (Baltimore, MD). He is director of urological research at the Radboud University Medical Center (1986-now). In 1996 Dr Schalken was (co) appointed as professor of experimental oncology at the University of Utrecht. Since 2001 he is professor of experimental urology at the Radboud University (Nijmegen).
His research has a strong translational component, i.e. conducting life sciences research to accelerate healthcare outcomes, specific themes
1. Unravelling the mechanism of (GU) cancer invasion/cadherin switching/EMT
2. Cancer stem/initiating cells
3. Targeted therapy in (GU) cancer
4. Molecular diagnostics (eg PCA3, SelectMDx)
5. Combining 1 thru 4 to make steps towards precision medicine
Howard I. Scher, MD is Chief of the Genitourinary Oncology Service at Memorial Sloan Kettering Cancer Center (MSKCC), Professor of Medicine at the Weill Cornell Medical College, and the D. Wayne Calloway Chair in Urologic Oncology. Dr. Scher’s research is focused on the codevelopment of targeted therapies and biomarkers such as circulating tumor cells (CTCs) which can be used to guide treatment selection for the individual patient and improve the way drugs are evaluated in the clinic, accelerating regulatory approvals. Accordingly, he has led international efforts to standardize the design and analysis of phase II prostate cancer trials (PCWG2, PCWG3) and helped elucidate key molecular and genetic features of prostate cancer, translating these insights into the clinic by leading early phase and phase III registration trials of abiraterone acetate and enzalutamide which are now FDA approved. Dr. Scher serves as the principal investigator of the NIH Specialized Program of Research Excellence.
Professor Bertrand Tombal is Chairman of the Division of Urology at the Université catholique de Louvain (UCL), Cliniques universitaires Saint-Luc, Brussels, Belgium.
He is the current chairman of the Clinical Trial Division of the European Organization for Research and Treatment of Cancer (EORTC), the leading European academic research organization in the field of cancer.
He has both a basic science and a clinical interest in urological oncology, particularly in the field of prostate and bladder cancer. B. Tombal obtained his MD in 1990 and his PhD in 2003, both from the UCL. B. Tombal’s primary clinical interest is the treatment of advanced stages of prostate cancer, and particularly hormonal treatment and development of new biological agents. He is heading the uro-oncology division at the Université catholique de Louvain where he is coordinating several trials in this research area.
Jeroen van Moorselaar studied medicine at the University of Nijmegen in the Netherlands and obtained his medical degree in June 1987. In 1991 he obtained his PhD degree on ‘Cytokine Therapy in Experimental Urological Cancer’. He was certified as urologist in June 1997. From that time he has worked in the University Hospital in Nijmegen in the urological department and in April 1998 he moved to the University Hospital in Utrecht where he worked until August 2005. In September 2005 he became the head of the urological outpatient department at the VU University Medical Centre in Amsterdam where he still works, but since August 2008 in the position of Chairman. In March 2011 he was appointed as Professor of Urology. He is member of various national and international organizations. He is member of the Dutch working party on urological oncological guidelines and is founding member of the Dutch UroOncology Study group. Since May 2007 he is board member of the European School of Urology. Furthermore he is member of the Examination Committee of the European Board of Urology. He is an active researcher in the field of urological oncology.
H. Van Poppel, MD, PhD, graduated in General Surgery in 1980, in Urology in 1983 and joined the Academic Unit at KU Leuven in 1985 after his postgraduate training in London, Barcelona, Copenhagen, Mainz and Rotterdam. In 1988, he obtained a PhD in Medical Sciences. He became a Fellow of the European Board of Urology (FEBU) in 1992, full Professor of Urology in 1993, and chair of the department of urology in Leuven in 2002. He was visiting Professor in several countries all over the world, were he demonstrated live uro-oncologic surgery for kidney, bladder and prostate cancer.
He described the original surgical technique for prepubic urethrectomy, percutaneous gastrostomy, lumbal splenectomy during orthotopic kidney transplantation, and of the Leuven “N”pouch for bladder substitution and performed more than 2500 radical prostatectomies
He has published 209 papers as first author on uro-oncology and has co-authored more than 370 and (co-)edited several books on kidney / prostate cancer
Dr. Vargas is a specialist in Oncologic and Molecular Imaging, currently the Director of Genitourinary Radiology at Memorial Sloan Kettering Cancer Center in New York. His clinical and research interests focus on the use of advanced imaging modalities, including diffusion-weighted and dynamic contrast-enhanced MRI and novel PET tracers for the non-invasive diagnosis, staging, treatment response assessment and follow-up of patients with cancer. Dr. Vargas is especially interested in imaging of patients with cancers involving the urinary system (e.g. prostate, bladder, and kidneys) and the female reproductive organs (e.g. uterus and ovaries).
Assistant Professor Urology
Master of Arts in management of health care institutions
Board certified Urologist
Research fellow at the Cancer Prognostics and Health Outcomes Unit at the University of Montréal /Canada
Residency: University of Hamburg/Germany and Marseille/France
Medical School: University of Mainz/Germany
Head of Urology, Institut Paoli-Calmettes Cancer Centre
Former Chairman EAU Section of Urological Imaging (ESUI)
Main activity in Urooncology
-Imaging in Urology
Imaging and Diagnosis
-Minimal invasive surgery
Since 2013 I’m chief of the Molecular Imaging and Therapy Service, Department of Radiology, Director of the Laurent and Alberta Gerschel Memorial PET Center at Memorial Sloan Kettering Cancer Center and Professor of Radiology at Weill Cornell Medical College. I completed my medical degree and residency training at the Technical University of Munich in Germany.
I authored more than 150 peer reviewed, original publications and review articles, and supervised more than 50 undergraduate students, graduate students, postdoctoral researcher, medical residents and fellows.
My current research is focused on the development and clinical evaluation of novel radiopharmaceuticals for the diagnosis and therapy of cancer. Ongoing projects include clinical and preclinical somatostatin and gastrin releasing peptide receptor antagonists for the diagnosis of therapy of neuroendocrine tumors and prostate cancer as well as imaging of PARP expression.
H.J.P. Wester studied chemistry/radiochemistry and carried out his PhD thesis in Radiopharm. Chem. at the Res. Center Jülich (G. Stöcklin). In 2006, he started his research activities at the Technical University Munich at the Department Nuclear Medicine (M.Schwaiger). Today, he is full professor for Pharm. Radiochem. at the Technical University Munich. Some prominent tracers developed in his group are F-18-FET, RGD-peptides, F-18-DPN, Pentixafor, Pentixather, Avebetrin, Ga-68 labeled TRAP complexes, PSMA I&T and PSMA I&S. He was member of the Board of the German Society of Nuclear Medicine, is member of the Board of the Bavarian Society of Nuclear Medicine and co-speaker of the Collaborative Research Center SFB824 of the German Research Foundation. He is founder of SCINTOMICS (2006), was CEO until 07.2015 and is now member of the advisory board. His main interest is the development and transfer of innovative diagnostic and therapeutic radiopharmaceuticals, i.e. peptides.